Myeloid‐derived suppressor cells in malignant melanoma
Myeloid‐derived suppressor cells in malignant melanoma
复制标题
DOI：
10.1111/ddg.12411
复制
发表时间：
2014-11
期刊：
影响因子：
--
通讯作者：
V. Umansky;A. Sevko;C. Gebhardt;J. Utikal
中科院分区：
文献类型：
--
作者：
V. Umansky;A. Sevko;C. Gebhardt;J. Utikal
黑色素瘤以其快速进展、转移到远处器官和治疗抗性而闻名。尽管黑色素瘤具有很高的免疫原性，但免疫学临床研究的结果大多不令人满意。一种解释是由高度免疫抑制的调节性白细胞，特别是髓源性抑制细胞（MDSC）介导的强烈免疫抑制的发展。发现这些细胞在黑色素瘤微环境中富集和活化，诱导抗肿瘤免疫应答的严重损害并导致肿瘤进展。因此，了解MDSC的产生，迁移到肿瘤部位和激活的机制以及它们的靶向对于开发有效的黑色素瘤免疫治疗的新策略是重要的。我们认为，这种治疗方法应该包括抑制MDSC介导的免疫抑制性黑色素瘤微环境，并结合其他免疫治疗。
Melanoma is known for its rapid progression, metastasis to distant organs and therapeutic resistance. Despite high melanoma immunogenicity, the results of immunotherapeutic clinical studies are mostly unsatisfactory. One explanation is the development of strong immunosuppression mediated by highly immunosuppressive regulatory leukocytes, in particular, myeloid‐derived suppressor cells (MDSCs). These cells were found to be enriched and activated in the melanoma microenvironment, inducing a profound impairment of anti‐tumor immune responses and leading to the tumor progression. Therefore, understanding the mechanisms of MDSC generation, migration to the tumor site and activation as well as their targeting is important for the development of novel strategies for effective melanoma immunotherapy. We suggest that such therapeutic approaches should involve the inhibition of MDSC‐mediated immunosuppressive melanoma microenvironment combined with other immunologic treatments.